NF-κΒ and SOD expression in preeclamptic placentas by SILVA CARMONA, ABRAHAM et al.
783
http://journals.tubitak.gov.tr/medical/




NF-κΒ and SOD expression in preeclamptic placentas
Abraham SILVA CARMONA1, Hugo MENDIETA ZERÓN2,3,*
1Hospital General de México, SSA, Mexico City, Mexico
2Asociación Científica Latina (ASCILA), Ciprés Grupo Médico (CGM), Toluca, Mexico
3Maternal-Perinatal Hospital “Mónica Pretelini Sáenz” (HMPMPS), Health Institute of the State of Mexico (ISEM), Toluca, Mexico
* Correspondence: mezh_74@yahoo.com
1. Introduction
Preeclampsia is a multisystemic and multifactorial 
disease and complicates 2%–8% of pregnancies after 20 
weeks of gestation, being the leading cause of maternal 
death in developing countries and a major contributor to 
maternal and perinatal morbidity. Globally, preeclampsia 
and eclampsia account for 10%–15% of maternal deaths. 
The majority of these deaths in developing countries 
result from eclampsia, while in developed countries, 
complications of preeclampsia are more often the cause 
(1). In Mexico, preeclampsia represents up to 34% of 
all maternal deaths, being the leading cause of death-
associated pregnancy complications (2,3). There is a 
certain type of complex inheritance in this disease: some 
studies postulate that persons with a familial history 
of preeclampsia are more susceptible to this disease. 
For example, Darcy et al. described that women with 
preeclampsia were 2.3 times more likely to have a female 
sibling who also had preeclampsia (4). A study carried 
out by Esplin et al. also found that both men and women 
who were the product of a pregnancy complicated by 
preeclampsia were significantly more likely than control 
men and women to have a child who was the product 
of a pregnancy complicated by preeclampsia (5). The 
greater likelihood of preeclampsia among relatives with 
a previous preeclamptic pregnancy is consistent with the 
pathophysiological role for genetics and/or behavioral 
factors that cluster in families.
Normal pregnancy exhibits an increase in free radical 
(FR) production; in parallel, antioxidant defenses also 
increase the maintenance of balance in the redox state (6). 
In contrast to normal pregnancy, there is an imbalance 
in the redox state in preeclampsia, i.e. women with 
preeclampsia exhibit an increased production of FRs 
and, at the same time, a decrease in several important 
antioxidants, generating oxidative stress (OS) with 
consequent damage to the entire class of important 
molecules such as DNA, proteins, unsaturated fatty acids, 
etc., and overstimulation of lipid peroxidation (7,8). 
During a preeclampsia-complicated pregnancy, catalase 
activity increases and superoxide dismutase (SOD) and 
glutathione reductase (GR) activity decreases compared 
with the same parameters during physiological pregnancy 
(9).
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Recently, it is has come to be known that, in addition 
to the direct damage that FRs can inflict on the molecules, 
imbalance in the redox state can alter the normal 
expression of various signaling pathways that comply 
with the physiological functions necessary to maintain the 
organisms’ homeostasis (10,11). One of these signaling 
pathways is the nuclear factor-kappa beta (NF-κΒ) 
pathway (12). This transcription factor is critical for a 
wide range of physiological processes, such as immunity, 
cell development, growth, and survival; however, aberrant 
activation of NF-κΒ could lead to morbid states (13). The 
aim of this study was to compare NF-κΒ and SOD gene 
expression in women who had suffered preeclampsia or 
not with or without familial history.
2. Materials and methods
This was a cross-sectional, prospective, nonrandomized, 
and descriptive study developed from March 2012 to 
February 2013, approved by the Ethics Committees of 
the Maternal-Perinatal Hospital “Mónica Pretelini Saénz” 
(HMPMPS) (2010-12-156), Health Institute of the State 
of Mexico (ISEM), and the Medical Sciences Research 
Center (CICMED), Autonomous University of the State of 
Mexico (UAEMex) (2010/02), and performed according to 
the ethical standards of the Helsinki Declaration of 1964. 
Written informed consent was obtained from all patients.
2.1. Patients
Pregnant women were recruited at the HMPMPS, 
ISEM, Toluca, Mexico. All subjects with chronic medical 
disorders such as diabetes mellitus, cardiovascular disease, 
autoimmune disease, chronic renal disease, chronic 
hypertension, collagen disorder, and other chronic disease 
were excluded. 
Four groups were formed as follows: a) normal 
pregnancies; b) normal pregnancies with familial history 
of preeclampsia; c) women with preeclampsia with familial 
history of preeclampsia, and d) women with preeclampsia 
without familial history of preeclampsia. The definition 
of and the criteria for preeclampsia were based on the 
diagnostic criteria outlined by the American College 
of Obstetrics and Gynecology (14). The sample was 
considered at convenience during the year of follow-up.
2.2. Clinical measurements
Weight (kg), height (m; Seca, GmbH, Germany), and waist 
circumference (cm) of all participants were measured in 
the morning. Body mass index was calculated as weight 
(kg) divided by height (m) squared. Blood pressure 
was recorded at each patient visit using a standard 
sphygmomanometer (Riester Big Ben® Square, Germany) 
with an appropriately sized cuff.
2.3. Laboratory analysis 
All patients underwent standard care, including routine 
laboratory tests, with an 8-h fasting period: albumin (mg/
dL); cholesterol (mg/dL); creatinine (mg/dL); glucose 
(mg/dL); triglycerides (mg/dL); uric acid (mg/dL); liver 
profile (Dimension R × L Max; Dade Behring, USA), 
and hematological parameters (Advia 120; Bayer Health, 
Germany). All these tests were measured at the HMPMPS 
according to standardized procedures recommended by 
the International Federation of Clinical Chemistry and 
Laboratory Medicine. 
2.4. Placental samples
Placental tissue samples were isolated a few minutes after 
delivery. Tissues were dissected from the maternal side in 
areas free of visible infarction, calcification, hematoma, or 
tears. The dimensions of each sample were approximately 
1‒3 cm3 and 100 mg wet weight. The basal and chorionic 
plates were removed, and each sample was washed 
three times with ice-cold calcium and magnesium-
free phosphate-buffered saline solution. Immediately 
afterward, the tissue was stored at –80 °C until analysis. 
2.5. mRNA extraction
The samples were homogenized using a Bullet Blender 
Standard BBX24 instrument (Next Advance, Inc., USA). 
Messenger RNA (mRNA) was extracted using the Magna 
Pure LC RNA isolation kit III (Roche, Germany) in the 
Magna Pure LC 2.0 Instrument. The A260/280 nm absorbance 
ratio was >1.8 (quality) and total RNA concentration 
was calculated by determining absorbance at 260 nm 
established with the NanoPhotometer (Implen GmbH, 
Germany). 
2.6. cDNA synthesis
A total of 200–400 ng of total mRNA was reverse-
transcribed to complementary DNA (cDNA) using a 





GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; NF-κΒ: nuclear factor-
kappa-beta, SOD2: superoxide dismutase 2.
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Transcriptor High Fidelity cDNA Synthesis Kit (Roche). 
The samples were measured with a NanoPhotometer 
(Implen GmbH), and the extracts were then adjusted to a 
concentration of 20 µg of DNA for the PCR reaction. 
The primers used in the experiments were designed 
using the Primer Quest web tool (Integrated DNA 
Technologies, Inc., USA) and synthesized at the 
Synthesis and DNA Sequencing Unit of the National 
Autonomous University of Mexico (UNAM) Institute of 
Biotechnology (Cuernavaca, Morelos, Mexico). A BLAST 
search was performed on primer sequences to ensure 
oligohybridization of only specific products. The sequences 
of the primers used in the analysis are depicted in Table 2. 
Real-time quantitative polymerase chain reaction 
(qPCR) was performed with the 7500 Fast Real Time PCR 
System (Applied Biosystems, Applera UK, Cheshire, UK). 
The final reaction volume (20 µL) contained 10 µL of SYBR 
Advantage qPCR premix (2X), 0.4 µL of each forward and 
reverse oligonucleotide, 0.4 µL of ROX Reference Dye 
LSR or LMP (50X), 2 µL of template, and 6.8 µL of dH2O 
(SYBR Advantage q-PCR Premix; Clontech, USA). The 
final concentration of each gene was optimized according 
to the final results calculated with the Taguchi method. 
The thermal cycling conditions were as follows: 10 min at 
95 °C followed by 45 cycles of denaturation at 95 °C for 15 
s and annealing/extension at 60 °C for 1 min. 
The fold change in NF-κΒ and SOD was normalized 
against glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and then compared with the untreated controls 
(calibration sample) with the delta-delta-(CT) method 
(2–ΔΔCT) as follows: = (CT-target – CT-reference) treated-
sample – (CT-target – CT-reference) calibrator-sample, 
where CT = threshold cycle. Calibrator-sample refers to 
the expression level (1×) of the target gene normalized to 
the constitutive gene. The calibrator was chosen from the 
group of women with normal pregnancies without familial 
history of preeclampsia.
2.7. Statistical analysis
Anthropometric and laboratorial results were presented 
as median (range), and those of genetic expression were 
presented as mean ± standard error (SE). The Mann–
Whitney U test was used for variables that were not 
normally distributed. The normality hypothesis was tested 
utilizing the Kolmogorov–Smirnov test. Statistical analysis 
was performed using SPSS 20.0. In all cases, P ≤ 0.05 was 
considered statistically significant.
3. Results
3.1. General patient characteristics
We studied 31 pregnant women with mean age of 22.3 ± 3.4 
years: eight with normal pregnancies, eight with normal 
pregnancies but with familial antecedents of preeclampsia, 
seven with preeclampsia without familial history, and 
seven with preeclampsia with familial history. 
Taking into account all women with a previous case 
of preeclampsia in their family (N = 15), the mothers 
Table 2. Clinical and laboratorial characteristics.1
Group
Variable Healthy pregnancies Healthy pregnanciesa Preeclampsia Preeclampsiaa
Age (years)**& 20.5 (17–25) 24 (17–25) 25 (22–29) 22 (16–26)
BMI (kg/m2) 26.2 (19.3–40) 26.6 (23.2–33.3) 28.6 (22.5–32.9) 31.2 (22.5–33.1)
Pregnancies 2 (1–4) 2.5 (1–4) 1 (1–2) 1 (1–5)
Prenatal consultations 6.5 (5–9) 6 (5–8) 6 (5–7) 5 (2–7)
Baby weight (kg) 3 (2.9–3.8) 2.8 (2.2–3.7) 3.6 (2–4) 2.9 (2.4–3.8)
SBP (mmHg)**ŧ 111.5 (104–125) 121 (88–145) 138 (100–152) 133 (110–150)
DBP (mmHg)*ŧ 68 (59–85) 73 (49–88) 81 (67–106) 80 (70–90)
MBP (mmHg)*ŧ 83.3 (74–98.3) 89.8 (69–107) 100 (78.7–121.3) 96 (90–110)
Leukocytes (cells/mm3) 7500 (6000–15,300) 9000 (6100–12,300) 8900 (4500–14,000) 7700 (6300–10,200)
Erythrocytes (cellsb/mm3) 4.5 (3.8–5.3) 4.5 (4.1–4.7) 4.4 (3.7–4.9) 4.2 (4–4.9)
Hb (g/dL) 13.5 (9.7–15.2) 13.3 (12.1–14.3) 13.2 (8.9–14.9) 12.7 (10.9–14.9)
Platelets (cellsc/mm3) 235 (108–269) 216 (165–376) 145 (122–263) 181 (147–313)
1Median (range); BMI: body mass index, Hb: hemoglobin, SBP: systolic blood pressure, DBP: diastolic blood pressure, MBP: median 
blood pressure. a: With family history for preeclampsia, b: millions, c: thousands. &: Difference between healthy women and preeclamptic 
women with familial history; ŧ: difference between healthy women and preeclamptic women without familial history.
*: P < 0.05; **: P < 0.01.
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represented 40% (N = 6) and their female siblings 60% of 
the affected relatives (N = 9).
Primi- or multiparous women with a new sexual 
partner constituted 50% (4 of 8) of the healthy group of 
pregnancies without a familial history of preeclampsia, 
37.5% (3 of 8) of the healthy group of pregnancies with 
familial history, 71.4% (5 of 7) of the group of women with 
preeclampsia without familial history, and 85.7% (6 of 7) 
of the group of women with preeclampsia with familial 
history. 
There were statistical differences in systolic (P < 0.01), 
diastolic (P < 0.05), and mean blood pressure (P < 0.05) 
between healthy women and women with preeclampsia 
without familial history. The only difference between 
healthy women and pregnant women with preeclampsia 
with familial history was in age (P < 0.01). Among 
laboratory data, there were no statistical significant 
differences in the hematological variables (Table 2).
When comparing the two groups with preeclampsia, 
women with affected relatives showed lower levels of 
uric acid (P < 0.05). Lactate dehydrogenase exhibited 
a tendency to be higher in the group with affected first-
degree relatives (P = 0.053).
3.2. Gene expression
Upon analyzing the normalized CT values with the 
Kruskal–Wallis test, there were no statistically significant 
differences in either the expression of NF-κΒ or SOD 
among the four groups (Table 3) (Figures 1A and 1B). 
Notwithstanding the lack of statistical difference, there was 
a reduction of about 33.33% in SOD expression in women 
with preeclampsia versus women with preeclampsia 
without familial history. Regarding NF-κΒ, there was 
an increase of 23.35% in the group of women with 
preeclampsia versus women with preeclampsia without 
familial history. When including all of the patients, only 
in two groups, that is, normal pregnancies and those of 
women with preeclampsia, was there also no difference in 
genetic expression.
4. Discussion
A large amount of investigation has shown a genetic 
association between a multifactorial polygenic inheritance 
and the development of preeclampsia (15). The risk of 
developing preeclampsia is increased five times in women 
with first-degree relatives with this disease, while those 
with second-degree relatives with the disease have their 
risk doubled (16). However, paternal genes may also play 
an important role in the development of preeclampsia, 
because the risk of this disease is increased in women with 
the pregnancies of men who have previously been involved 
in pregnancies complicated by preeclampsia (17).
Over 70 biological candidate genes have been 
examined, representing pathways involved in various 
pathophysiological processes, including vasoactive 
proteins, thrombophilia, hypofibrinolysis, OS and lipid 
metabolism, endothelial injury, and immunogenetics 
(18,19). These findings and others suggest a multifactorial 
polygenic inheritance with a genetic component in the 
development of this disease (20). In analyzing OS, SOD 
probably possesses a tendency to be decreased in women 
with a familial history of preeclampsia.
Even more, several microarray studies have analyzed 
the transcriptome of preeclamptic placentas for identifying 
genes that could be involved in placental dysfunction. 
Some of the promoters of upregulated genes are enriched 
in putative binding sites for NF-κΒ (21), which determines 
an inflammatory response (22). Contrariwise, specific 
inhibitors of p38 mitogen-activated protein kinase and 
NF-κΒ, but not protein kinase C signaling pathways, can 
reduce the stimulatory effect of interleukin-1 beta (23). 
It has only been in recent years, as susceptibility genes 
for other complex disorders have been reported, that 
the effect of the small size of individual genetic variants 
have become apparent, the majority increasing the risk 
for disease by <50% (24). In this study, we compared 
NF-κΒ and SOD expression in pregnant women with or 
without preeclampsia and familial history of this disease. 
Although there were expected changes in the relative 
expression of both genes when there was familial history 
for preeclampsia, these modifications were not sufficiently 
strong to achieve statistical difference.
A limitation of this study is the small sample size of each 
group; however, investigation concerning preeclampsia is 
time-consuming and, similar to other studies (25,26), we 
Table 3. Relative gene expression.1
Group
Gene Healthy pregnancies Healthy pregnanciesa Preeclampsia Preeclampsiaa
NF-κΒ 4.84 (2) 3.29 (1.1) 6.55 (3.1) 8.08 (1.7)
SOD 3.17 (2.8) 6.68 (3.3) 2.82 (1.2) 1.88 (0.7)
1Median (standard error [SE]). NF-κΒ: Nuclear factor-kappa-B, SOD: superoxide dismutase. a: With family 
history for preeclampsia.
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think that analysis of novel molecules is valid in a small 
population as an initial approach.
While it is noteworthy that no one gene will be identified 
as the sole risk factor for preeclampsia, interactions 
among numerous pathways activated by several genes 
and/or single nucleotide polymorphisms, in addition to 
predisposing environmental factors, are most likely to 
underscore the genetic component of this disorder 
Our study implies that the familial presence of 
preeclampsia could predispose to an altered expression 
in SOD and NF-κΒ, partially explaining the genetic 
background that predisposes to a higher risk of this disease. 
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